TRANSTHYRETIN AMYLOID CARDIOPATHY
Clinical trials for TRANSTHYRETIN AMYLOID CARDIOPATHY explained in plain language.
Never miss a new study
Get alerted when new TRANSTHYRETIN AMYLOID CARDIOPATHY trials appear
Sign up with your email to follow new studies for TRANSTHYRETIN AMYLOID CARDIOPATHY, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Experimental heart drug pulled before first patient enrolled
Disease control TerminatedThis study aimed to test a monthly injection called ION-682884 in people with TTR amyloid cardiomyopathy, a condition where abnormal protein deposits damage the heart. Only patients who had already completed a 2-year study of a similar drug (inotersen) were eligible. The goal was…
Matched conditions: TRANSTHYRETIN AMYLOID CARDIOPATHY
Phase: PHASE2 • Sponsor: Brigham and Women's Hospital • Aim: Disease control
Last updated Jun 27, 2026 09:07 UTC
-
New registry tracks how ATTR-CM patients are treated in daily practice
Knowledge-focused OngoingThis study is a disease registry that collects information from routine medical care of about 350 adults diagnosed with transthyretin amyloid cardiomyopathy (ATTR-CM) in Taiwan, Hong Kong, and Malaysia. Researchers will look at patient characteristics, treatments received, and ho…
Matched conditions: TRANSTHYRETIN AMYLOID CARDIOPATHY
Sponsor: Pfizer • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:06 UTC